Myriad Genetics, Inc.

NasdaqGS:MYGN Stok Raporu

Piyasa değeri: US$369.3m

Myriad Genetics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Myriad Genetics şirketinin kazançları yıllık ortalama -34.2% oranında azalırken, Biotechs sektörünün kazançları yıllık 33.8% oranında artan oldu. Gelirler yıllık ortalama 6.4% oranında artan oldu.

Anahtar bilgiler

-34.22%

Kazanç büyüme oranı

-30.04%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.04%
Gelir büyüme oranı6.43%
Özkaynak getirisi-118.52%
Net Marj-48.24%
Son Kazanç Güncellemesi31 Mar 2026

Yakın geçmiş performans güncellemeleri

Recent updates

Anlatı Güncellemesi • Apr 21

MYGN: 2026 Turnaround And Pipeline Milestones Will Keep Sentiment Cautious

Analyst price targets on Myriad Genetics have moved slightly lower, with recent cuts to $6 from $8 and $6.50, as analysts wait for clearer evidence of progress on the turnaround plan, pipeline milestones, and improved growth and profitability before shifting their stance. Analyst Commentary Recent Street research reflects a cautious stance on Myriad Genetics, with bearish analysts trimming price targets and highlighting execution and growth risks despite some operational positives.
Anlatı Güncellemesi • Apr 05

MYGN: 2026 Turnaround Execution And Pipeline Delivery Will Sustain Bearish Caution

Analysts have trimmed their price targets on Myriad Genetics to a range of $6 to $7, reflecting caution around the pace of the turnaround and the need for clearer progress on growth, profitability and pipeline execution before taking a more constructive stance. Analyst Commentary Recent research updates point to a cautious tone, with several bearish analysts trimming price targets into the US$6 to US$7 range and maintaining neutral ratings.
Seeking Alpha • Mar 31

Myriad Genetics: SOTP Suggests The Company Is Undervalued

Summary Myriad Genetics, Inc. has grown from a mainly Hereditary Cancer business into a broader precision medicine company, but the market still values it at a low multiple because earnings, cash flow, and. The strongest part of the business is still the core Hereditary Cancer franchise, which has shown better resilience than other units through stronger volume trends and steadier operating performance. Even on a conservative sum-of-the-parts basis, the stock appears undervalued, with an estimated value of about $6.05 per share versus the current market price. Followed by portfolio simplification can bring further upside. Near-term catalysts in 2026, including HCT Precise MRD customer testing, the planned AI-enabled Prolaris launch, and continued cost discipline, could help narrow the valuation gap. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Mar 21

MYGN: Turnaround Execution In 2026 Will Drive Continued Cautious Sentiment

The Street’s blended price target for Myriad Genetics has shifted lower into a $6 to $7 range as analysts factor in updated sector models, reiterated 2026 guidance, and the need for clearer progress on the company’s turnaround and profitability before becoming more constructive. Analyst Commentary Recent research updates show a clear tilt toward caution, with several bearish analysts trimming their valuation ranges for Myriad Genetics and keeping ratings in the middle of the scale rather than moving to a more positive stance.
Anlatı Güncellemesi • Mar 06

MYGN: Turnaround Execution And 2026 Pipeline Milestones Will Drive Bearish Outlook

Analysts have trimmed their price targets on Myriad Genetics to a range of about $6 to $7, reflecting more cautious assumptions on growth and profitability even as they acknowledge recent results and the company’s ongoing turnaround efforts. Analyst Commentary Recent research updates show bearish analysts trimming price targets on Myriad Genetics into a tighter band around $6 to $7, signaling a more cautious stance on the stock even as they acknowledge operational progress.
Anlatı Güncellemesi • Feb 19

MYGN: Rebased Outlook Weighs Execution Risks Against Upcoming MRD Commercialization Potential

Analysts have adjusted their outlook on Myriad Genetics, trimming the average price target to $7 from $9. They have also updated their assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E based on recent diagnostics sector research and expectations for solid results and 2026 guidance.
Analiz Makalesi • Feb 13

Little Excitement Around Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues As Shares Take 27% Pounding

To the annoyance of some shareholders, Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares are down a considerable 27% in the...
Anlatı Güncellemesi • Feb 05

MYGN: Sector Fundamentals And New Diagnostics Partnerships Will Support A More Constructive Outlook

Analysts have lowered their price target on Myriad Genetics to $7 from $9, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, while still expecting solid diagnostics sector results and 2026 outlooks. Analyst Commentary Recent research on Myriad Genetics focuses on how the updated $7 price target lines up with expectations for the broader diagnostics group, where analysts still see solid sector results and 2026 outlooks supported by what they describe as strong fundamentals.
Analiz Makalesi • Feb 04

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Anlatı Güncellemesi • Jan 22

MYGN: Sector Strength And Expanded Cancer Testing Will Support Future Upside

Narrative Update Analysts have adjusted their view on Myriad Genetics, reflected in a higher fair value estimate from $14.33 to $16.06 as they weigh mixed price target moves in recent research and slightly different assumptions for growth, margins, and future P/E. Analyst Commentary Recent Street research on Myriad Genetics presents a mixed but informative picture, with some caution on price targets alongside more constructive adjustments that support the updated fair value estimate.
Anlatı Güncellemesi • Jan 08

MYGN: Sector Strength And New Partnerships Will Support A More Constructive Outlook

Narrative Update The analyst price target for Myriad Genetics has shifted modestly lower, with a blended change of roughly $1 across recent moves to $7 and $8. Analysts are factoring in updated diagnostics sector expectations and revising their fair value estimates and P/E outlooks for the company.
Anlatı Güncellemesi • Dec 24

MYGN: Rising Margin Visibility Will Support A More Constructive Bullish Outlook

Analysts have raised their price target on Myriad Genetics shares from $6.00 to $8.00, reflecting modest improvements in long term profit margin expectations and valuation assumptions, while maintaining a neutral overall outlook. Analyst Commentary Analyst commentary around the revised price target highlights a generally balanced view, with recognition of incremental progress offset by lingering execution and profitability concerns.
Anlatı Güncellemesi • Dec 10

MYGN: Improved Earnings Visibility Will Shape Bullish Outlook

Analysts have modestly raised their price target on Myriad Genetics to $8 from $6, reflecting a slightly higher fair value estimate supported by improved forward price to earnings assumptions and a marginally higher discount rate that still preserves cautious revenue growth expectations. Analyst Commentary Analyst sentiment around Myriad Genetics remains balanced, with the higher price target reflecting modest improvements in forward expectations rather than a decisive shift in outlook.
Anlatı Güncellemesi • Nov 26

MYGN: Breast Cancer Risk Collaboration And Margin Gains Will Shape Outlook

Narrative Update on Myriad Genetics Analysts have raised their price target for Myriad Genetics from $6 to $8, citing improved profit margins and modest revenue growth as key drivers for the upward revision. Analyst Commentary Analyst opinions about Myriad Genetics reflect a mix of optimism regarding the company's recent performance and continued caution around potential challenges.
Anlatı Güncellemesi • Nov 12

MYGN: Expanded Cancer Testing Is Expected To Drive Future Gains

Narrative Update on Myriad Genetics Analysts have increased their price target for Myriad Genetics from $6 to $8. This adjustment reflects revised expectations based on updates to fair value assessments, discount rates, and future earnings metrics.
Anlatı Güncellemesi • Oct 29

Adding Cancer Test Capabilities And Mental Health Data Will Support Long-Term Progress

Analysts have slightly raised their price target for Myriad Genetics to approximately $7.95 from $7.77 per share. They cited modest improvements in expected profit margins and updated assumptions around discount rates.
Anlatı Güncellemesi • Oct 14

Expanding Oncology Testing And Genomic Profiling Will Widen Market Reach

Analysts have adjusted their price target for Myriad Genetics upward from $7.38 to $7.77, citing minor improvements in profit margin and future price-to-earnings expectations, even though revenue growth projections have been slightly reduced. What's in the News Myriad Genetics has formed a strategic partnership with SOPHiA GENETICS to develop and globally deploy a liquid biopsy companion diagnostic test for pharmaceutical companies, leveraging both companies' expertise and international networks (Strategic Alliances).
Analiz Makalesi • Sep 30

Estimating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Key Insights Myriad Genetics' estimated fair value is US$8.13 based on 2 Stage Free Cash Flow to Equity Myriad...
Analiz Makalesi • Aug 17

Myriad Genetics, Inc. (NASDAQ:MYGN) Held Back By Insufficient Growth Even After Shares Climb 28%

NasdaqGS:MYGN 1 Year Share Price vs Fair Value Explore Myriad Genetics's Fair Values from the Community and select...
Analiz Makalesi • Jun 25

Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Those holding Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares would be relieved that the share price has rebounded 29% in...
Analiz Makalesi • May 09

Lacklustre Performance Is Driving Myriad Genetics, Inc.'s (NASDAQ:MYGN) 48% Price Drop

To the annoyance of some shareholders, Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares are down a considerable 48% in the...
User avatar
Yeni Anlatı • Mar 24

PATHOMIQ AI Partnership Will Expand Oncology And Women's Health

Strategic partnerships and investments in AI and women's health aim to enhance oncology offerings and capture larger market shares, driving revenue growth.
Analiz Makalesi • Mar 16

Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31%

Myriad Genetics, Inc. ( NASDAQ:MYGN ) shareholders that were waiting for something to happen have been dealt a blow...
Analiz Makalesi • Feb 26

Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results

There's been a notable change in appetite for Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares in the week since its annual...
Seeking Alpha • Jan 16

Myriad Genetics: Navigating Through A Setback

Summary Myriad Genetics, Inc.'s stock value has halved recently, despite Q3 results released in early November beating expectations. Management has succeeded in reducing GAAP net losses, but has a new challenge with policy changes from United Healthcare that took effect at the beginning of this year. This has impacted FY2025 initial guidance and cratered the stock over the past nine weeks. Are MYGN shares in the 'buy zone' yet?  An analysis of Myriad Genetics follows in the paragraphs below. Read the full article on Seeking Alpha
Analiz Makalesi • Jan 08

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued

Key Insights Using the 2 Stage Free Cash Flow to Equity, Myriad Genetics fair value estimate is US$26.22 Current share...
Analiz Makalesi • Nov 13

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Last week, you might have seen that Myriad Genetics, Inc. ( NASDAQ:MYGN ) released its quarterly result to the market...

Gelir ve Gider Dağılımı

Myriad Genetics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:MYGN Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
31 Mar 26829-400538106
31 Dec 25825-366538107
30 Sep 25825-400549114
30 Jun 25833-395550114
31 Mar 25831-101555116
31 Dec 24838-127560113
30 Sep 24824-116563102
30 Jun 24802-15556098
31 Mar 24774-23556291
31 Dec 23753-26357389
30 Sep 23734-27458791
30 Jun 23699-24858188
31 Mar 23695-14655187
31 Dec 22678-11251585
30 Sep 22661-7744483
30 Jun 22672-1849481
31 Mar 22682-851380
31 Dec 21691-2753882
30 Sep 21684-5759980
30 Jun 21662-9754278
31 Mar 21566-14851476
31 Dec 20557-22450173
30 Sep 20598-19449974
30 Jun 20639-19950777
31 Mar 20761-14853981
31 Dec 19813-2654683
30 Sep 19835-1554786
30 Jun 19851555786
31 Mar 198302351283
31 Dec 187962647980
30 Sep 187675445174
30 Jun 1874413343571
31 Mar 1874913044472
31 Dec 1776312645971
30 Sep 1777110147273
30 Jun 177291744074
31 Mar 177573244675
31 Dec 167516341475
30 Sep 167489438573
30 Jun 1674111735971
31 Mar 1675712134970
31 Dec 1574710834969
30 Sep 157389535170
30 Jun 157238036676

Kaliteli Kazançlar: MYGN şu anda kârlı değil.

Büyüyen Kar Marjı: MYGN şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: MYGN kârlı değildir ve zararlar son 5 yılda yılda 34.2% oranında artmıştır.

Büyüme Hızlandırma: MYGN 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: MYGN kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 43% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: MYGN hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -118.52% ) sahiptir.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/22 23:15
Gün Sonu Hisse Fiyatı2026/05/22 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Myriad Genetics, Inc. 37 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Jack MeehanBarclays
Derek TallerBenchmark Company
Michael RyskinBofA Global Research